XML 23 R13.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Co-Promotion Agreement | 9 Months Ended
--- | ---
Sep. 30, 2022
Co Promotion Agreement [Abstract] |
Co-Promotion Agreement | (7) Co-Promotion Agreement On March 31, 2014, the Company entered into a Co-Promotion Agreement, or the Agreement, with Kowa Pharmaceuticals America, Inc. related to the commercialization of VASCEPA capsules in the United States. The Company and Kowa Pharmaceuticals America, Inc. intentionally designed the Agreement to naturally end as of December 31, 2018 and mutually agreed not to renew the Agreement. During 2018, which was the last year of the co-promotion of VASCEPA by Kowa Pharmaceuticals America, Inc., the Company incurred expense for co-promotion tail payments which are calculated as a percentage of the 2018 co-promotion fee, which was eighteen and a half percent (18.5%) of VASCEPA gross margin in 2018. The accrued tail payments are paid over three years with declining amounts each year. Kowa Pharmaceuticals America, Inc. was eligible to receive $17.8 million in co-promotion tail payments, the present value of which $16.6 million, was fully accrued as of December 31, 2018. During the first quarter of 2022, the final co-promotion tail payment was made to Kowa Pharmaceuticals America, Inc. As of December 31, 2021, a net payable to Kowa Pharmaceuticals America, Inc. of $0.6 million was classified as current on the condensed consolidated balance sheet, representing the remaining accrued co-promotion tail payments.

X
- Definition Co-promotion agreement. + References No definition available. + Details
Name: | amrn_CoPromotionAgreementAbstract
Namespace Prefix: | amrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Co promotion agreement disclosure. + References No definition available. + Details
Name: | amrn_CoPromotionAgreementDisclosureTextBlock
Namespace Prefix: | amrn_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration